Mark D. Matteucci
Geen lopende functies
Loopbaan van Mark D. Matteucci
Eerdere bekende functies van Mark D. Matteucci
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01-01-1988 | 01-01-1999 |
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Hoofd Techniek/Wetenschap/O&O | 01-08-2002 | - |
| Corporate Officer/Principal | 01-08-2002 | - |
Opleiding van Mark D. Matteucci
| Massachusetts Institute of Technology | Undergraduate Degree |
| The University of Colorado | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 5 |
Operationeel
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Finance | 2 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
- Beurs
- Insiders
- Mark D. Matteucci
- Ervaring
